Press Room


    Press Release - September 04, 2001

    Pamela Wallin Appointed to Pheromone Sciences Board of Directors

    Pheromone Sciences Corp (CDNX:PHS), is pleased to announce the appointment of Ms. Pamela Wallin, renowned Canadian journalist, broadcaster and businesswoman, to its Board of Directors.

    Ms. Wallin brings a wealth of knowledge to the Pheromone Sciences' Board of Directors given her long- standing interest in women's health issues and an outstanding media career that has spanned some twenty- five years. Television journalist and author, Ms. Wallin currently hosts Pamela Wallin's Talk TV for the CTV group. Her latest book, Speaking of Success: Collected Wisdom, Insights and Reflections is scheduled to be published in September. Ms. Wallin has garnered a long list of awards during her career including the United Nations UNIFEM Canada Award for outstanding contributions toward the advancement of women and the Saskatchewan Order of Merit, the provinces highest honour to thank those who have dedicated their lives to improving their communities.

    Ms. Wallin is very active in community affairs. Amongst her activities she currently sits on the Board of Directors of the University Health Network in Toronto, the Board of Governors of the University of Waterloo and she is a patron of the Genesis Research Foundation, Advancing Women's Health. She was educated at the University of Regina receiving an honours degree in psychology and political science and has since been awarded honorary degrees from the University of Western Ontario, Ryerson Polytechnic University, Wilfrid Laurier University and Loyalist College.

    "Ms. Wallin is a wonderful addition to the Board of Directors," commented Dr. William Cochrane, Chairman of Pheromone Sciences Corp. "Through a combination of media experience, entrepreneurship and public policy interest that is unmatched in Canada, Pamela will bring a broader perspective to the Company."

    The appointment, which is subject to regulatory approval, is part of an ongoing program to enhance the independent nature of the Board.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News